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Abstract
Background: Most children with Inflammatory Bowel Disease (IBD) are diagnosed between 11 and 16 years of age,
commonly presenting with features of typical IBD. Children with onset of gut inflammation under 5 years of age
often have a different underlying pathophysiology, one that is genetically and phenotypically distinct from other
children with IBD. We therefore set out to assess whether children diagnosed after the age of 5 years, but before
the age of 11, have a different clinical presentation and outcome when compared to those presenting later.
Methods: Retrospective cohort study conducted at two European Paediatric Gastroenterology Units. Two cohorts
of children with IBD (total number = 160) were compared: 80 children diagnosed between 5 and 10 years (Group
A), versus 80 children diagnosed between 11 and 16 (Group B). Statistical analysis included multiple logistic
regression.
Results: Group A presented with a greater disease activity (p = 0.05 for Crohn’s disease (CD), p = 0.03 for Ulcerative
Colitis (UC); Odds Ratio 1.09, 95 % Confidence Interval: 1.02–1.1), and disease extent (L2 location more frequent
amongst Group A children with CD (p = 0.05)). No significant differences were observed between age groups in
terms of gastro-intestinal and extra-intestinal signs and symptoms at disease presentation, nor was there a
difference in the number of hospitalisations due to relapsing IBD during follow-up. However, children in Group A
were treated earlier with immunosuppressants and had more frequent endoscopic assessments.
Conclusion: While clinicians feel children between 5 and 10 years of age have a more severe disease course than
adolescents, our analysis also suggests a greater disease burden in this age group. Nevertheless, randomized trials
to document longer-term clinical outcomes are urgently needed, in order to address the question whether a
younger age at disease onset should prompt per se a more “aggressive” treatment. We speculate that non-clinical
factors (e.g. genetics, epigenetics) may have more potential to predict longer term outcome than simple clinical
measures such as age at diagnosis.
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Background
The incidence of Inflammatory Bowel Disease (IBD) is
rising worldwide, with a current mean prevalence in the
general population estimated at 1/1,000 inhabitants in
Europe and North America, and a rising trend observed
in developing countries [1, 2]. Although patients may
develop IBD at any age, currently approximately 10–
25 % of patients are diagnosed during childhood or ado-
lescence [3–7]. The majority of children diagnosed with
IBD will present between 11 and 16 years of age. How-
ever, in recent years the reports of children diagnosed
below the age of 10 years seems to be steadily increasing
[8–12]. While a more aggressive presentation and dis-
ease behaviour has been well established for children di-
agnosed under the age of 5 years (i.e. early onset and
very early onset IBD) [13–18], little is currently known
about specific differences in phenotype and disease out-
come for children diagnosed between 5 and 10 years of
age. Previous reports have indicated that the age of dis-
ease onset correlates inversely with disease outcome,
suggesting that younger age, even amongst children,
may represent an important risk factor for an aggressive,
treatment-resistant disease phenotype [19–24].
A so-called ‘step-up’ treatment approach remains
standard practice in most European centres, which, at
least in part, is due to the lack of validated prognostic
markers that can identify high risk individuals. There are
no studies that identify any aspects of disease phenotype
that accurately predict disease course and outcome for
an individual patient.
However, more recent evidence suggests that earlier
use of more effective treatments (i.e. ‘top-down’ ap-
proach) in patients improves long-term outcome [25].
In this study, we therefore aimed to assess whether
children diagnosed with IBD between their 5th and 11th
birthday differ significantly in disease phenotype, course
and response to treatment, when compared to children
diagnosed in later childhood.
We compared two groups of children diagnosed be-




This retrospective cohort study was conducted at two
tertiary Paediatric Gastroenterology Units, in Cambridge
- United Kingdom, and in Padua - Italy. Patients en-
rolled were all diagnosed between 2009 and 2013 to en-
sure a minimum follow-up of 12 months.
Ethical approval for the study was obtained from both
Institutions (Cambridge University Hospitals NHS FT,
Department of Paediatric Gastroenterology, IBD Internal
Audit - Cambridge, UK; Medical Ethics Committee at
the Department of Women’s and Children’s Health -
Padua University, Padova, Italy). Each patient recruited
and their parents/guardians were given appropriate in-
formation for consent.
A total of 287 patients from the two countries were
eligible for the study. Plotting the distribution of their
age at diagnosis of IBD, we also identified 11 years as
the value separating the lowest quartile of children (5–
10 yeras) from the rest (11–16 yeras). Hence, this age
cut-off was chosen as a suitable watershed between the
two age groups, as it also represents a plausible bound-
ary line between childhood and adolescence, and as vari-
ous age cut-offs (i.e. 10,11 and 12 years of age) have
been used in previous descriptive studies [7–9, 24].
We therefore selected children diagnosed between 5
and 10 years of age (Group A) and those diagnosed be-
tween 11 and 16 (Group B).
A total of 160 patients were selected from children in
each service as this number was available in each unit
and age-group. Patients were grouped as follows: 80
children in Group A (40 British and 40 Italians), and 80
children in Group B (40 British and 40 Italians)
(Table 1).
The groups from the United Kingdom (UK) and from
Italy were comparable in age of disease onset: 7.65 ±
2.38 (mean age (years) ± standard deviation) for British
Group A v. 7.4 ± 3.1 for Italian Group A; 14.1 ± 1.03 for
British Group-B v. 13.4 ± 1.39 for Italian Group B (Fur-
ther demographic data on Table 1).
Data collection, clinical phenotype and outcome
measurement
Clinical and outcome data were collected from patients’
records (paper notes and electronic databases). The
same researcher (MG) was solely and directly involved
in data collection. He was employed as a trainee doctor
in both centres for longer than 1 year in each Institution.
Therefore, the data collection was homogenous and was
conducted with full awareness of the similarities and dis-
similarities in protocols and practice between the two
centres.
An Excel database was set up and appropriate software
packages (including Graph Pad Prism version 6.4 and
SAS statistical package version 9.4) were used for further
statistical analysis of data.
In order to compare the children in Group A to the
ones in Group B, a number of clinical variables were
agreed a priori for collection from each patient in the
four subgroups.
To depict the characteristics of the disease at diagno-
sis, we considered all clinical and biochemical variables
included in the Paediatric Crohn’s Disease Activity Index
(PCDAI) [26] and in the Paediatric Ulcerative Colitis Ac-
tivity Index (PUCAI) [27]. Disease location was reported
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according to the Paris classification, basing on endo-
scopic findings [28].
The clinical variables collected for each patient at
diagnosis, were the following:
– Abdominal pain: none, mild (can be ignored), severe
(cannot be ignored);
– Stool consistency of most stools: formed, partially
formed, completely unformed;
Table 1 Distribution of the patients enrolled, grouped by age at diagnosis (group A, 5 to 10 years, versus group B, 11 to 16 years of
age at diagnosis), by type of Inflammatory Bowel Disease, gender and ethnicity. Disease location, CD behaviour, Growth (for CD) and
Severity (for UC) are also displayed according to the Paris Classification [28]
Age at diagnosis Brita Group A




(5 to 10 years)
Ita Group B
(11–16 years)
Patients’ number 40 40 40 40
Distribution by gender 23 Mc 17 Fd 25 M 15 F 15 M 25 F 20 M 20 F
Age at diagnosis
Mean ± SDe 7.65 ± 2.38 14.1 ± 1.03 7.4 ± 3.1 13.4 ± 1.39
Median 8.34 14.3 7.9 13.5
Range 5.1–10.6 11.4–16.6 5.6–10.8 11.2–16.3
Distribution by type
of IBDf
15 CDg 19 CD 16 CD 22 CD
4 IBD-Uh CD-like 5 IBD-U CD-like 1 IBD-U CD-like 1 IBD-U CD-like
12 UCi 7 UC 15 UC 15 UC
9 IBD-U UC-like 9 IBD-U UC-like 8 IBD-U UC-like 2 IBD-U UC-like
Follow-up duration (years)
Mean ± SD 3.1 ± 2.3 1.92 ± 1.19 4.5 ± 3.71 2.21 ± 2.4
Median 2.8 1.72 4.2 1.17
Range 0.1–11.14 0.3–4.62 0.04–11.7 0.07–9.5
Ethnicity 36 white British 38 white British 34 white Italians 38 white Italians
3 white non-British
(Belgium, Italy, Romania)
1 white non British
(Turkey)
6 white non-Italians (2 from
Romania, 2 from Moldova,
1 from Kosowo, 1 Gipsy)
1 white non-Italian
(Romania)




CD CD CD CD
2 L1 + L4a 1 L1/2 L1 + L4a/1 L1 + L4b 1 L1 2 L1/2 L1 + L4a
2 L2/4 L2 + L4a 1 L2 + L4a 5 L2/1 L2 + L4a 1 L2/1 L2 + L4a
9 L3 + L4a/2 L3 + L4b 3 L3/16 L3 + L4a 3 L3/7 L3 + L4a 10 L3/7 L3 + L4a
UC UC UC UC
1 E1/2 E2 1 E1/2 E2 1 E1/7 E2 2 E1/4 E2
1 E3/17E4 2 E3/11 E4 1 E3/14 E4 2 E3/9 E4
CD behaviour (Paris
Classification [28])
11 B1, 5 pB1 11 B1, 4 pB1 10 B1, 2 pB1 5 B1, 5pB1
1 B2 5 B2 1 B2, 1 pB2 10 B2, 1 pB2
1B3 1 B3, 1 pB3 1pB3 1 pB3
1pB2B3 1 B2B3, 1 pB2B3 1 B2B3, 1 pB2B3 1 B2B3
CD growth (Paris
Classification [28])
4 S1 3 S1 3 S1 2 S1






f IBD inflammatory bowel disease
gCD Crohn’s disease
hIBD-U inflammatory bowel disease unclassified
iUC ulcerative colitis
Gasparetto et al. BMC Gastroenterology  (2016) 16:35 Page 3 of 11
– Number of stools per 24 h: 0–2, 3–5, 6–8, >8;
– Rectal bleeding: none, small amount only - in less
than 50 % of stools, small amount with most stools,
large amount (50 % of the stool content);
– Nocturnal stools (any episode causing wakening);
– Patient functioning - general well-being within
the last week: no limitation of activities - well,
occasional difficulties in maintaining age appropriate
activities - below par, frequent limitation of
activities - very poor;
– Weight: weight gain or voluntary weight loss,
involuntary weight loss 1–9 %, weight loss >10 %;
– Height: < 1 channel decrease (or height velocity > −
SD), > 1 <2 channel decrease (or height velocity < −
1 SD > − 2 SD), >2 channel decrease (or height
velocity < −2 SD);
– Abdomen on examination: no tenderness - no mass,
tenderness - or mass without tenderness, tenderness
- involuntary guarding - definite mass;
– Peri-rectal disease: none - asymptomatic tags, 1–2
indolent fistula - scant drainage - tenderness of
abscess, active fistula - drainage - tenderness or
abscess;
– Extra-intestinal manifestations including fever >38.5
for 3 days in a week, arthritis, uveitis, erythema
nodosum, pyoderma gangrenosum: none, one, two;
Amongst the clinical variables at diagnosis, we also re-
corded urgency - tenesmus, nausea - vomit, mouth ul-
cers and iron-deficiency anaemia.
The statistical analyses, aimed at comparing the two
age groups, were done on all IBD patients first, and
subsequently on subgroups by diagnosis (CD and UC)
(Table 2, Additional file 1: Table S1). Patients from
the two centres were first grouped and analysed sep-
arately; only as part of a second step were they
pooled together in order to compare the two age
groups irrespective of the country of origin. The mul-
tiple logistic regression analysis was first performed
including the country of origin as an independent
variable, with repeated analysis then disregarding this
variable.
The biochemical variables considered were the following:
– Haematocrit (%): <10 years of age (>33, 28–33, <28);
11–14 years of age/male (>35, 30–34, <30); 15–19
years of age/male (>37, 32–36, <32); 11–19 years of
age/female (>37, 32–36, <32);
– Erythrocyte sedimentation rate (ESR) (mm/h): <20,
20–50, >50;
– Albumin (g/L): >35, 31–34, <30.
We also recorded Haemoglobin, mean corpuscular
volume (MCV) and platelet count.
Also for the biochemical parameters, the statistical
analyses aimed at comparing the two age groups were
performed first on all IBD patients, and subsequently on
CD patients and UC patients separately (Table 2,
Additional file 1: Table S1 B).
For disease follow-up there is currently no validated
clinical score that can provide a meaningful summary
outcome measure. As no composite ‘damage’ score
yet exists that defines overall disease burden, we still
lack an accurate measure of cumulative disease
burden.
In the absence of this, we considered a number of var-
iables, referring to the main outcome measures investi-
gated in a number of clinical studies on paediatric and
adult IBD patients:
– Incremental treatment escalation included: 5-
Aminosalicilates (5-ASA), exclusive enteral nutrition
(EEN), antibiotics, steroids, thiopurines, biologics
(Infliximab, Adalimumab), surgical intervention;
– Number of disease relapses per patient, per year of
follow-up (definition of disease relapse as provided
below in this paragraph);
– Number of endoscopies per patient, per year of
follow-up;
– Number of unplanned inpatient and outpatient days,
per patient, per year of follow-up.
As an additional investigation, Group A and B chil-
dren were compared by country of origin and age group
in order to explore potential differences in clinical
phenotype, treatments, and disease outcome.
Disease relapse was defined as a PCDAI score [26] of
above 30 for CD, or a PUCAI score [27] of above 35 for
UC. Both must have persisted for at least a week despite
ongoing immunosuppressant treatment. Patients with a
PCDAI score between 10 and 30 or with a PUCAI score
between 10 and 35 for longer than 2 weeks, and despite
ongoing immunosuppressant treatment for IBD, were
also considered as having a relapse. A confirmation of
disease relapse by endoscopic and histological re-
assessment was also available for more than 80 % of the
patients enrolled in this study, but endoscopy was not
considered a mandatory parameter to define a relapse of
disease.
Treatment escalation in this study was defined as a)
any switch from a less potent to a more potent immuno-
suppressant, b) a disease relapse occurring on estab-
lished maintenance therapy. The order of increasing po-
tency was 5-ASA, oral steroids, i.v. steroids, thiopurines,
biologics/surgical interventions.
Any re-induction treatment for disease relapse during
the follow-up (e.g. any new course of steroids) was con-
sidered as treatment escalation.
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Table 2 Comparison between children in group A (age at diagnosis of Inflammatory Bowel Disease between 5 and 10 years) and
those in group B (age at diagnosis of Inflammatory Bowel Disease between 11 and 16 years): disease activity and location at
presentation (A), biochemical parameters at disease presentation (B), disease course and outcomes (C)
Variables All Group A vs Group B Brita Group A vs Group B Itab Group A vs Group B
A. Disease activity and location at presentation
Disease activity
CDc (PCDAId)
Group A: mean ± SDe 38.75 ± 2.7 45 ± 3.3 31.3 ± 3.44
Group B:mean ± SD 30.76 ± 2.02 32.2 ± 2.26 29.6 ± 3.5
P 0.05 0.003 0.7
UCf (PUCAIg)
Group A: mean ± SD 47.2 ± 2.5 55.2 ± 2.2 41.2 ± 2.7
Group B: mean ± SD 41.4 ± 1.8 41.6 ± 2.5 39.8 ± 3.65
P 0.03 0.03 0.8
ORh 1.09 1.11 1.03
95 % CIi 1.02–1.1 1.03–1.2 1.01–1.08
Disease location
CD
P 0.3 for L1 0.6 for L1 0.3 for L1
0.05 for L2 0.04 for L2 0.7 for L2
0.4 for L3 0.5 for L3 0.7 for L3
UC
P 0.7 for E1–E2 0.8 for E1–E2 0.6 for E1–E2
0.8 for E3–E4 0.9 for E3–E4 0.9 for E3–E4
B. Biochemical parameters at disease presentation
WBCj (x10^3/mm3)
Group A: mean ± SD 10.1 ± 0.45 10.9 ± 0.7 9.4 ± 0.6
Group B: mean ± SD 8.81 ± 0.35 9.09 ± 0.5 8.5 ± 0.47
P 0.03 0.04 0.3
HCTk (%)
Group A: mean ± SD 33.7 ± 0.57 32.6 ± 0.6 34.8 ± 0.9
Group B: mean ± SD 35.8 ± 0.5 34.9 ± 0.7 36.7 ± 0.6
P 0.005 0.02 0.09
Platelet count (x10^3/mm3)
Group A: mean ± SD 487 ± 18.9 476 ± 21.3 497.5 ± 31.2
Group B: mean ± SD 393 ± 13.4 404 ± 18.6 382 ± 19.3
P 0.002 0.01 0.003
C. Disease course and outcomes
Early treatment with thiopurines (within 3 months of diagnosis)
Group A 58 20 38
Group B 46 17 29
P 0.05 0.7 0.006
OR 1.86 1.04 7.19
95 % CI 1.02–4.33 0.8–2.63 0.9–77.4
Relapses (per patient/per year of follow-up)
Group A: mean ± SD 1.4 ± 0.2 1.53 ± 1.24 1.03 ± 0.3
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Any induction treatment at diagnosis was not taken as
treatment escalation.
An increase in dose due to weight gain was not con-
sidered as a treatment escalation, whereas an increase in
dose of biologic (e.g. Infliximab, from 5 to 10 mg/Kg) or
a reduction of the time between infusions (e.g., Inflixi-
mab from 8 to 6 weeks) due to loss of response, were
both considered treatment escalations.
Any change in therapy made on the basis of parent/
family preference, rather than on the basis of a clinical
decision by the healthcare team, was not considered as
treatment escalation.
Statistical analysis
First, a descriptive statistical analysis was conducted for
each clinical variable using the following tests:
– The Chi-Square test was used as a test of association
for categorical variables. It allowed us to identify the
existence of a correlation between a categorical variable
(e.g. perianal disease at diagnosis, per rectal bleeding at
diagnosis etc.) and one of the two age groups;
– For each categorical variable, a Fisher’s exact test
was also used, given the small size of our cohort
subsets;
– An unpaired student t-test was used to compare
continuous variables (e.g. laboratory parameters)
with normal distribution and similar standard
deviation between the two age groups, irrespective
of sample size being equal between the groups;
– Paired t-tests were used to compare the means of
continuous variables between the two age groups,
assuming a normal distribution but different stand-
ard deviations;
– Welch’s adaptation of Student’s t test was used when
the two samples had unequal variances and unequal
sample sizes;
– Mann – Whitney U test (or Wilcoxon rank-sum
test) was used to compare continuous variables in
the two groups, when the distribution was non-
normal.
As a second step, we performed a multiple logistic re-
gression analysis, using the SAS Statistical Package, ver-
sion 9.1 (SAS Institute Inc, Cary, NC).
Multiple logistic regression analysis was performed to
detect if and how independent variables (i.e. age at diag-
nosis, +/− country of origin) would influence disease
presentation (i.e. phenotypic features at diagnoses in-
cluding abdominal pain, weight loss, nocturnal symp-
toms, anaemia, joint pain; lab tests including albumin,
CRP and ESR; disease activity scores, i.e. PCDAI and
PUCAI) and disease outcomes (e.g. number of relapses
per year, number of endoscopies per year, activity index
at the latest follow-up (PCDAI, PUCAI), early treatment
with thiopurines etc.).
We used a step-wise approach in order to weigh each
single variable irrespective of the other variables (i.e. to
remove inter-variable dependancy). The analysis was
conducted in three main steps: first testing the variables
Table 2 Comparison between children in group A (age at diagnosis of Inflammatory Bowel Disease between 5 and 10 years) and
those in group B (age at diagnosis of Inflammatory Bowel Disease between 11 and 16 years): disease activity and location at
presentation (A), biochemical parameters at disease presentation (B), disease course and outcomes (C) (Continued)
Group B: mean ± SD 0.85 ± 0.1 0.9 ± 0.7 0.7 ± 0.13
P 0.05 0.005 0.3
OR 1.2 1.5 1.2
95 % CI 1.01–1.65 0.8–4.45 0.74–2.64
Number of endoscopies (per patient/per year of follow-up)
Group A: mean ± SD 0.9 ± 0.05 0.9 ± 0.06 0.9 ± 0.09
Group B: mean ± SD 0.75 ± 0.05 0.8 ± 0.07 0.7 ± 0.08
P 0.04 0.2 0.05
OR 1.67 1.2 7.07




dPCDAI paediatric Crohn’s disease activity index
eSD standard deviation
fUC ulcerative colitis
gPUCAI paediatric ulcerative colitis activity index
hOR odds ratio
iCI confidence interval
jWBC white blood cells
kHCT haematocrit
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relating to disease presentation at diagnosis (column 1
in Additional file 2: Table S2), second introducing the
variables relating to disease outcomes (column 2 in
Additional file 2: Table S2), finally inputting all variables
(column 3 in Additional file 2: Table S2).
Variables selected for the multiple logistic regression
analysis were based on the results obtained from the ini-
tial descriptive statistical analysis (comparison between
the groups for each variable, through the tests described
above). In fact, we selected those variables that were
significantly different between the two age groups at the
initial descriptive analysis, in order to investigate
whether such differences would be confirmed by the
multiple logistic regression analysis.
A p value <0.05 was considered as significant.
Results
Patients’ demographics, including distribution by age,
gender, ethnicity and type of IBD, are reported in
Table 1.
We observed a higher percentage of females in the
Italian Group A, which differs from what is reported in
most of the literature, with usually a higher percentage
of males found in the younger ages.
The vast majority of the patients enrolled in both units
were Caucasians, with very little ethnic diversity
(Table 1).
There was no significant difference in IBD-U fre-
quency between the two groups in this study (22 in
Group A; 17 in Group B). As this is a histological diag-
nosis, these results might have been expected to be
skewed by the involvement of different histopathologists,
however even within each centre there was no signifi-
cant difference between age groups. The overall percent-
age of IBD-U being in line with other published results
[5, 8, 10].
Comparison of clinical phenotype at disease onset
between two age groups
Children in Group A presented at diagnosis with a more
severe disease activity score (PCDAI: Mean 38.75 ± 2.7;
PUCAI: Mean 47.2 ± 2.5), compared to those in Group B
(PCDAI: Mean 30.76 ± 2.02; PUCAI: Mean 41.36 ± 1.8)
(p = 0.05 for CD, p = 0.03 for UC) (OR 1.09, 95 % CI
1.02–1.1) (Table 2a).
Using the Paris classification for IBD [28] to compare
patient groups for disease location at diagnosis, we ob-
served that an L2 location of CD was more frequent
amongst the children in Group A, compared to those
with later onset (p = 0.05) (Tables 1 and 2a). In accord-
ance with previous studies [30], we also found that
younger children had more extensive colonic involve-
ment (p = 0.05), whilst the older group presented with
more ileal disease.
There were no significant differences in clinical pheno-
type between children recruited in the UK and those re-
cruited in Italy. Comparing clinical signs and symptoms
at disease presentation, no remarkable differences
emerged in predictors between the two age groups; these
included gastrointestinal features (i.e. abdominal pain,
diarrhoea, vomiting, PR bleeding, weight loss, faecal
urgency), perianal disease and extra intestinal mani-
festations/associated diseases (e.g. joint involvement,
erythema nodosum, sclerosing cholangitis) (Additional
file 1: Table S1 A).
A more severe disease presentation amongst children in
Group A was noted when children from the two countries
(British and Italian) were analyzed separately. In particular,
British children with CD in Group A presented more
frequently with diarrhoea (p = 0.04), moderate-severe ab-
dominal pain (p = 0.009), and urgency (p = 0.05), com-
pared to those in Group B (Additional file 1: Table S1 A).
As for the Italian children, joint pain (extra intestinal
manifestation of IBD) and sclerosing cholangitis (diag-
nosed by MRCP/liver biopsy on the basis of increased
indexes of cholestasis) were observed more often at
diagnosis amongst the patients in Group A than
amongst those in Group B (p = 0.03 and p = 0.05 respect-
ively) (Additional file 1: Table S1 A).
Comparison of biochemical parameters between age
groups
Overall, we did not observe any reproducible and signifi-
cant differences in serum inflammatory makers (Table 2,
Additional file 1: Table S1 B) between groups.
Faecal calprotectin was only available in a limited
number of patients at diagnosis (four British Group A,
six British Group B, 17 Italians Group A, 20 Italians
Group B). When pooling all available calprotectin results
at diagnosis, we found that values over 300mcg/g were
present in the entire cohort, with the vast majority (45/
47) having values >600 mcg/g. Over all, there were no
significant differences observed between early and late
onset groups, or between different centres.
Interestingly, we found a significant difference in a
number of haematology indices. Children in Group A
presented with higher white blood cell count (WBC)
(p = 0.03), higher platelet count (p = 0.002), lower
haemoglobin (p = 0.03) and lower haematocrit (p =
0.005) (Table 2b, Additional file 1: Table S1 B).
More specifically, the British children in Group A
presented at diagnosis with a higher WBC count (p =
0.04 for all IBD, p = 0.02 for CD), lower hemoglobin level
(p = 0.04 for all IBD, p = 0.03 for CD), lower haematocrit
level (p = 0.02) and higher platelet count (p = 0.01 for all
IBD – p = 0.001 for CD) than those in Group B
(Additional file 1: Table S1 B).
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Amongst Italian children, those in Group A
presented at diagnosis with lower haematocrit level
(p = 0.09, ns; p = 0.02 for UC), and higher platelet
count (p = 0.003 – p = 0.0002 for UC), compared to
those in Group B (Additional file 1: Table S1 B).
Comparison of treatment requirements between the two
groups
No differences were found between the two age groups
for the number of patients treated with 5-ASA (p = 0.6),
exclusive enteral nutrition (p = 0.09), antibiotics (p = 0.5),
steroids (p = 0.2), biologics (p = 1 for Infliximab and for
Adalimumab), and for the number of children who
underwent surgical interventions (p = 0.5) (Additional
file 1: Table S1 C).
However, children in Group A were treated more fre-
quently with early thiopurines (within the first 3 months
after diagnosis) (p = 0.05) (Fig. 1b), which was also con-
firmed by the multiple logistic regression analysis (OR
1.86, 95 % CI 1.02–4.33; Table 2c, Additional file 2:
Table S2). In particular, this was observed for the Italian
children (P 0.006 for all IBD – P 0.05 for CD)
(Additional file 1: Table S1 C).
No significant differences were observed between
Group A and Group B, in the number of patients treated
with Infliximab (p = 0.6 for the British and p = 0.5 for the
Italians) (Fig. 1c and Additional file 1: Table S1 C).
Direct comparison between the cohorts from each
country aimed at highlighting differences in treatment
protocols between Cambridge and Padua, showing that
the British patients were treated more frequently with
steroids (p = 0.003 for Group A, p = 0.02 for Group B)
(Fig. 1a) and with iron supplements (p = 0.005 for
Group A) than Italian patients.
In comparison to the British, Italian children were
treated more frequently with antibiotics (p = 0.01 for
Group A, p = 0.006 for Group B) and with early
thiopurines (i.e. within 3 months from diagnosis) (p
<0.0001 for Group B) (OR 0.05, CI 0.01–0.21)
(Fig. 1b).
When comparing British children in Group A to the
Italians, no significant differences were observed in
terms of treatment with Infliximab (P 0.3). However, the
Italian children in Group B were treated with Infliximab
more frequently than their British equivalents (p = 0.03)
(Fig. 1c).
Fig. 1 Comparison between Group A (age at diagnosis 5–10 years) and Group B (age at diagnosis ≥11 years) for treatment with Steroids (a),
early treatment with Thiopurines (within 3 months of diagnosis) (b), Infliximab (c) and early treatment with Infliximab (top-down) (d). Brit British,
dg diagnosis, IFX Infliximab, Ita Italian, Num number, Pts patients, TP Thiopurines
Gasparetto et al. BMC Gastroenterology  (2016) 16:35 Page 8 of 11
Moreover, Italian children also received early treat-
ment with Infliximab (top down treatment) more fre-
quently than the British (p = 0.04 both for Group A and
for Group B) (Fig. 1d).
Seven children in Group A (three British, four Italians)
and five in Group B (four British, one Italian) required a
surgical intervention.
Overall, there were no statistically significant differ-
ences in respect to the number of surgical interventions
amongst the four groups of patients (p = 0.7 for the
British children, p = 0.17 for the Italian children)
(Additional file 1: Table S1 C).
Amongst the three British children who had surgery in
Group A, one had UC and two had IBD-U UC-like. Two
of them were treated with subtotal colectomy and ileos-
tomy, one with total colectomy and ileostomy.
Amongst the four Italian children who were operated
in Group A, two had CD and two had UC. The two chil-
dren with CD were treated with stricturoplasty (patient
1) and with ileal resection and drainage of abdominal
abscess (patient 2).
The four British children in Group B who underwent
surgery had CD. All of them were treated with laparo-
scopic ileo-caecal resection.
The Italian child in Group B had severe Crohn’s with
fistulising perianal disease. He underwent fistulotomy
and seton insertion, and was started on biologics.
Comparison of disease outcomes between the two age
groups
During follow-up, children in Group A relapsed more
frequently than the ones with later onset (relapses per
patient per year: mean 1.4 ± SD 0.2 for children with
earlier onset vs. 0.85 ± 0.1; p = 0.05, OR 1.2, 95 % CI
1.01–1.65) (Table 2c).
Moreover, younger children also underwent a higher
number of endoscopies (p = 0.04, OR 1.67, CI 1.01–4.19)
(Table 2c).
Younger children had more documented relapses dur-
ing their follow-up in Cambridge, whilst this group of
children underwent more endoscopic investigations in
Padua.
For the British patients, data on the number of un-
planned inpatient and outpatient days per patient, during
one year of follow-up, was also available: no significant dif-
ferences were found between the two age groups (p = 0.2
for the number of inpatient days and p = 0.4 for the num-
ber of outpatient days).
Discussion
The diagnosis of a chronic inflammatory bowel disease
at any age is a major life event. It is particularly trau-
matic in a child, as the burden of subsequent disease is
much greater, with potentially major effects on their
education, growth, psychological development and long-
term quality of life. It is clear that children diagnosed
with IBD under the age of five represent a unique dis-
ease group that is different to the more ‘typical’ IBD
phenotype. These are often caused by specific genetic
variations and/or rare abnormalities in immune defence
[13–18]. However, after the age of about 5 years, it is un-
certain if age itself remains a further predictor of disease
course and outcome.
To explore this hypothesis, we provide a detailed ana-
lysis of 160 children with IBD recruited in two large ter-
tiary European centres. We compared the lower quartile
of children aged 5–10 years with those aged 11–16
years, seeking to identify clinically useful differences be-
tween these two age groups.
The most significant distinction between age-groups
was that disease activity scores at diagnosis (PCDAI,
PUCAI) were higher amongst the younger group of chil-
dren (p = 0.05 for CD, p = 0.03 for UC). However these
scores are all based on retrospective calculation of dis-
ease activity, something that may compromise the valid-
ity of the statistical significance.
In addition, we found only minor differences on mul-
tiple logistic regression analysis (OR 1.09, 95 % CI 1.02–
1.1), suggesting further caution is required before claim-
ing clinically relevant differences at diagnosis.
We acknowledge that recruiting patients from two dif-
ferent countries might introduce a significant geograph-
ical bias. As an example, disease activity at diagnosis was
more severe in the British Group A than in the older
group, whereas such difference was not significant
amongst the Italian children (Table 2). A difference in
disease activity at diagnosis was also observed once all
children are pooled together and the two age groups
were compared, which is likely to be driven by the Brit-
ish cohorts. In order to reduce biases in the downstream
analysis (e.g., treatment protocols and outcomes com-
pared between two populations of children who may
have differences related to their country of origin), the
statistical analysis for each variable was performed in
two steps: first comparing the two age groups within
each country, and subsequently pooling all children from
the different countries together, to compare the two age
categories on higher numbers. The multiple logistic re-
gression analysis was also performed twice, first consid-
ering and then disregarding the variable “country of
origin”. This hasn’t really reflected on any other signifi-
cant difference in terms of clinical phenotype, laboratory
parameters and outcomes between the two age groups.
Moreover, the primary aim of this study was to detect spe-
cific phenotypic and outcome differences in children diag-
nosed with IBD in different age groups, and we consider
that any consistent differences age-related should have
emerged in our study, irrespective of the country of origin.
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Some of the variables we analysed were objective pa-
rameters collected reliably from records held at both
centres (e.g. clinical signs and symptoms at diagnosis, la-
boratory results, number of surgeries etc.). A specific
comment is required in regard to joint involvement as
extra-intestinal manifestation (EIM) at disease presenta-
tion, which should be interpreted carefully, in view of
previous studies investigating the same parameter [29].
In fact, although our study was led by a single researcher
working in both centres, it was still a retrospective data
collection and analysis, meaning different clinicians
assessed the EIMs.
Although both units started children in the younger
age group at diagnosis on immunosuppressants more
frequently in the first 3 months (95 % of Italian
Group-A and 50 % of British Group-A), Italian ado-
lescents were given Infliximab sooner (15 % vs 2.5 %)
and more frequently (36.2 % vs 16.3 %) than their
British counterparts.
Parameters like type of medication, number of treat-
ment escalations per patient per year, endoscopies per
patient per year, etc. are all likely to be influenced by
local practice. Although this variability remains an in-
trinsic limitation of this study, it suggests clear variation
in treatment in the context of little difference in clinical
outcome. As outlined in the methods section, we did do
our best to standardise data collection as far as possible.
Our findings clearly demonstrate different clinical ap-
proaches to treatment with immunomodulators and bio-
logics in each unit. The UK Unit typically employed a
“step-up” approach to treatment, reserving biologic
treatment as third line therapy, whilst the Italian Unit
showed a clear preference for a “top-down” strategy.
Both centres have unrestricted access to biological ther-
apy, making clinical indications the main drivers for use.
However, it is well known that Italian paediatric gastro-
enterology training and principals are more aligned with
US practice than with the European ‘step-up’ approach.
It is very telling therefore, that we identified only mod-
est differences in clinical outcome between children
treated with a ‘top-down’ rather than ‘step-up’ approach.
However, our findings do suggest that younger children
present with more severe disease, relapse more fre-
quently and are endoscoped more frequently than their
older counterparts – all despite earlier treatment with
both immunosuppressants (UK and Italy) and biologics
(Italy only). Furthermore the higher relapse rate in the
younger age group in the UK, should be seen in the con-
text of more steroid use and later intervention with
biologics.
On this basis, the question remains whether a
more aggressive treatment is still really justified in
children with disease onset between 5 and 10 years
of age?
Conclusion
In keeping with previous evidence on this topic, our
findings confirm a more extensive disease location and a
greater disease activity at presentation, in children diag-
nosed with IBD between the ages of 5 and 10 years,
compared to adolescents. Whilst the numbers in this
retrospective study are relatively small, our analysis also
suggests a greater disease burden in the younger chil-
dren (e.g. higher number of relapses and endoscopies).
However, randomised trials to document longer-term
clinical outcomes are urgently needed, in order to ad-
dress the question whether a younger age at disease on-
set should prompt per se a more “aggressive” treatment
(e.g. early immunosuppression, “top-down” use of
biologics).
Given the expanding research availabilities in IBD, we
speculate that new approaches (e.g. epigenetics, develop-
ment of new prognostic biomarkers) may be more help-
ful than simple clinical parameters, in order to predict
outcomes in different patient groups, to individualise
our decision-making and to personalise treatment at
diagnosis.
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